Clinical Trials Using Tremelimumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Tremelimumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-45 of 45

  • Durvalumab, Tremelimumab, and Selumetinib in Treating Patients with Recurrent or Stage IV Non-small Cell Lung Cancer

    This phase I / II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating patients with stage IV non-small cell lung cancer or that has come back. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving durvalumab, tremelimumab and selumetinib may work better in treating patients with non-small lung cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Durvalumab, Tremelimumab, and Radiation Therapy in Treating Participants with Intermediate Risk Head and Neck Squamous Cell Cancer

    This phase I trial studies how well durvalumab, tremelimumab, and radiation therapy work in treating participants with intermediate risk head and neck squamous cell carcinoma. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving durvalumab, tremelimumab, and radiation therapy may work better in treating participants with head and neck squamous cell carcinoma.
    Location: 2 locations

  • Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    This phase I / II trial studies the side effects of durvalumab, tremelimumab and hypofractionated radiation therapy in treating patients with head and neck squamous cell carcinoma that has come back or that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving durvalumab, tremelimumab, and hypofractionated radiation therapy may work better in treating patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

    This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
    Location: 2 locations

  • Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants with Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

    This phase I trial studies how well stereotactic body radiation therapy works in combination with tremelimumab and durvalumab in treating participants with cervical, vaginal, or vulvar cancers that have come back (recurrent) or spread to other areas of the body (metastatic). Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as tremelimumab and durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy, tremelimumab, and durvalumab may work better in treating participants with cervical, vaginal, or vulvar cancers.
    Location: 2 locations

  • Stereotactic Body Radiation Therapy, Durvalumab, and Tremelimumab in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This phase Ib trial studies the side effects of stereotactic body radiation therapy, durvalumab, and tremelimumab and to see how well they work in treating patients with stage IV non-small cell lung cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy, durvalumab, and tremelimumab may work better in treating patients with non-small cell lung cancer.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • A Phase I / II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

    Background: - Immune-based approaches in colorectal cancer have unfortunately with the notable exception of immune checkpoint inhibition in microsatellite instable (MSI-hi) disease been largely unsuccessful. The reasons for this are unclear but no doubt relate to the fact that in advanced disease colorectal cancer appears to be less immunogenic, as evidenced by the lack of infiltrating lymphocytes with advancing T stage - Pexa-Vec (JX-594) is a thymidine kinase gene-inactivated oncolytic vaccinia virus engineered for the expression of transgenes encoding human granulocyte- macrophage colony-stimulating factor (GM-CSF) and beta-galactosidase. Apart from the direct oncolytic activity, oncolytic viruses such as Pexa-Vec have been shown to mediate tumor cell death via the induction of innate and adaptive immune responses - Tremelimumab is a fully human monoclonal antibody that binds to CTLA-4 expressed on the surface of activated T lymphocytes and causes inhibition of B7-CTLA-4-mediated downregulation of T-cell activation. Durvalumab is a human monoclonal antibody directed against PD-L1. - The aim of the study is to evaluate whether the anti-tumor immunity induced by Pexa-Vec oncolytic viral therapy can be enhanced by immune checkpoint inhibition. Objective: -To determine the safety, tolerability and feasibility of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in patients with refractory metastatic colorectal cancer. Eligibility: - Histologically confirmed metastatic colorectal cancer. - Patients must have progressed on, been intolerant of or refused prior oxaliplatin- and irinotecan-containing, fluorouracil-based, chemotherapeutic regimen and have disease that is not amenable to potentially curative resection. Patients who have a known KRAS wild type tumor must have progressed, been intolerant of or refused cetuximab or panitumumabbased chemotherapy. - Patients tumors must be documented to be microsatellite-stable (MSS) either by genetic analysis or immunohistochemistry OR microsatellite-high with documented disease progression following anti-PD1 / PDL1 therapy. - Patients must have at least one focus of metastatic disease that is amenable to pre- and ontreatment biopsy. - Willingness to undergo mandatory tumor biopsy. Design: -The proposed study is Phase I / II study of Pexa-Vec oncolytic virus at two dose levels in combination with immune checkpoint inhibition in patients with metastatic colorectal cancer.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Durvalumab and Tremelimumab with Radiation or Ablation Therapy in Treating Patients with Metastatic Colorectal Cancer

    This phase II trial studies how well durvalumab and tremelimumab with radiation or ablation therapy work in treating patients with colorectal cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Radiofrequency ablation uses a needle to deliver a high-frequency, electric current to kill tumor cells by heating them. It is not yet known whether giving durvalumab and tremelimumab with radiation or ablation therapy may work better in treating patients with colorectal cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Durvalumab, Tremelimumab, and Radiation Therapy in Treating Participants with High Risk Soft-Tissue Sarcoma

    This phase I / II trial studies the side effects of durvalumab, tremelimumab, and radiation therapy and to see how well they work in treating participants with high risk soft-tissue sarcoma. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab, tremelimumab, and radiation therapy may work better at treating high risk soft-tissue sarcoma.
    Location: University of Maryland / Greenebaum Cancer Center, Baltimore, Maryland

  • Durvalumab and Tremelimumab in Treating Participants with Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether give durvalumab and tremelimumab in combination or sequential administration works better in treating participants with ovarian, primary peritoneal, or fallopian tube cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Azacitidine, Durvalumab, and Tremelimumab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    This phase Ib trial studies the best dose of azacitidine when given together with durvalumab and tremelimumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving azacitidine, durvalumab, and tremelimumab may work better in treating patients with head and neck squamous cell carcinoma.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

    BACKGROUND: - Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response. The term ablative therapies applies to trans-arterial catheter chemoembolization (TACE), radiofrequency ablation (RFA) and cryoablation (CA). - The underlying hypothesis of this study is that the effect of immune checkpoint inhibition can be enhanced by TACE, CA and RFA in patients with advanced hepatocellular carcinoma (HCC) and biliary tract carcinomas (BTC). We have already demonstrated proof of principle as well as safety and feasibility of this approach with anti-CTLA4 therapy. - Based on the concept of PDL1-mediated adaptive resistance and the emerging role of PD1 therapy in HCC, we would like to evaluate the combination of tremelimumab and durvalumab (with ablative therapies) in HCC and BTC. Objectives: - To preliminarily evaluate the 6-month progression free survival (PFS) of combining tremelimumab and durvalumab in patients with advanced HCC (either alone or with cryoablation, TACE or RFA) and in patients with advanced biliary tract carcinoma (BTC) (either alone or with cryoablation or RFA). ELIGIBILITY: - Histologically or cytologically confirmed diagnosis of HCC or biliary tract carcinoma OR histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of HCC (or biliary tract carcinoma). - Childs-Pugh A / B7 cirrhosis only is allowed. If patient does not have cirrhosis, this limitation does not apply. - Patients must have disease that is not amenable to potentially curative resection, radiofrequency ablation, or liver transplantation. DESIGN: We will evaluate the combination of tremelimumab and durvalumab (with ablative therapies) in cohorts A (HCC; N=40) and B (BTC; N=30). The first N=10 patients in both cohorts will receive tremelimumab and durvalumab only (i.e. No interventional radiologic procedures). - A: Advanced HCC, BCLC# Stage B / C - N= 1st 10 pts: No ablative procedure Cryoablation / RFA / TACE## - Tremelimumab 75mg flat dose q28 days for 4 doses; Durvalumab 1500mg flat dose q28 days until EOS### - 40 total: 10 trem+ dur alone; 10 trem+ dur + TACE; 10 trem + dur + RFA; 10 trem + dur + cryo - B: Intra / extra-hepatic cholangiocarcinoma - N= 1st 10 pts: No ablative procedure; RFA / cryoablation - Tremelimumab 75mg flat dose q28 days for 4 doses; Durvalumab 1500mg flat dose q28 days until EOS### - 30 total: 10 trem+ dur alone; 10 trem + dur + RFA; 10 trem - BCLC = Barcelona clinic liver cancer staging system - For BCLC stage B patients TACE may be repeated as per standard of care - EOS = End of study treatment or meeting any of the off-treatment or off study criteria.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Durvalumab and Tremelimumab in Treating Patients with Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated with Cisplatin-Based Therapy before Surgery

    This pilot phase I trial studies the side effects of durvalumab and tremelimumab in treating patients with muscle-invasive, high-risk urothelial cancer that cannot be treated with cisplatin-based therapy before surgery. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Tremelimumab and Durvalumab in Treating Patients with Colorectal Cancer with Liver Metastases That Can Be Removed by Surgery

    This phase I trial studies the side effects and how well tremelimumab and durvalumab work in treating patients with colorectal cancer that has spread to the liver and can be removed by surgery. Immunotherapy with monoclonal antibodies, such as tremelimumab and durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Hypofractionated Radiation Therapy, Durvalumab, and Tremelimumab in Treating Patients with Metastatic Relapsed or Refractory Melanoma, Non-small Cell Lung Cancer, Breast Cancer, or Pancreatic Cancer

    This phase I trial studies the side effects of hypofractionated radiation therapy, durvalumab, and tremelimumab when given together in treating patients with melanoma, lung, breast, or pancreatic cancers that have spread to other places in the body (metastatic) and have returned (come back) after a period of improvement (relapsed) or does not respond to treatment (refractory). Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and may have fewer side effects than standard radiation therapy. Monoclonal antibodies, such as durvalumab and tremelimumab, may block tumor growth in different ways by targeting certain cells. Giving hypofractionated radiation therapy together with durvalumab and tremelimumab may kill more tumor cells.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Durvalumab with or without Tremelimumab in Treating Participants with Resectable Malignant Pleural Mesothelioma

    This phase II trial studies how well durvalumab with or without tremelimumab works in treating participants with malignant pleural mesothelioma that can be removed by surgery. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Tremelimumab with or without Olaparib in Treating Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This randomized phase I / II trial studies the side effects and best dose of tremelimumab with or without olaparib in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has not responded to treatment or has come back after treatment. Immunotherapy with monoclonal antibodies, such as tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs, such as olaparib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tremelimumab with olaparib may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Stereotactic Body Radiation Therapy and Durvalumab with or without Tremelimumab before Surgery in Treating Participants with Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

    This phase Ib / II trial studies the side effects and how well stereotactic body radiation therapy and durvalumab with or without tremelimumab before surgery work in treating participants with human papillomavirus positive oropharyngeal squamous cell cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy and durvalumab with or without tremelimumab before surgery may work better, and cause fewer short and long-term side-effects, in participants with oropharyngeal squamous cell cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

    A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
    Location: See Clinical Trials.gov

  • Tremelimumab and Durvalumab in Treating Patients with Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery

    This phase II trial studies how well tremelimumab and durvalumab work in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. Monoclonal antibodies such as tremelimumab and durvalumab, may interfere with the ability of tumor cells to grown and spread. Giving tremelimumab with durvalumab may be a better way to treat malignant pleural mesothelioma.
    Location: See Clinical Trials.gov